P2RY1 Gene

Introduction

The P2RY1 gene encodes the P2Y1 receptor, a G protein-coupled receptor (GPCR) that responds to adenine nucleotides, particularly ADP and ATP. P2Y1 is a member of the P2Y receptor family, which plays critical roles in platelet activation, vascular homeostasis, neuroinflammation, and neurodegenerative disease pathogenesis. Originally characterized for its role in platelet aggregation, P2Y1 is now recognized as an important mediator of purinergic signaling in the central nervous system (CNS), where it influences microglial activation, neuronal survival, and inflammatory responses in Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative disorders. ^{1P2Y receptors in the nervous system2001 · Prog Neurobiol · PMID 11263679Open reference}

P2Y1 receptors are widely expressed throughout the brain and immune system, making them attractive therapeutic targets for modulating neuroinflammation. Unlike the P2X7 receptor (which forms ion channels), P2Y1 is a metabotropic receptor that signals through Gq proteins, activating phospholipase C (PLC) and leading to intracellular calcium mobilization. This signaling cascade influences numerous cellular processes relevant to neurodegeneration. ^{2Purinergic signalling in the nervous system2006 · Nat Rev Neurosci · PMID 16715049Open reference}

Gene Overview

Gene Structure

Genomic Architecture

The P2RY1 gene is located on chromosome 19p13.2 and consists of 2 exons spanning approximately 4.5 kilobases. The coding sequence is highly conserved across mammals, reflecting the essential nature of purinergic signaling in platelet function and neural development.

Transcriptional Regulation

P2RY1 expression is regulated by:

1. Promoter elements: TATA-less promoter with GC-rich regions and multiple Sp1 binding sites

2. Cytokine regulation: TNF-α and IL-1β can modulate P2RY1 expression

3. Cell type specificity: Strong expression in platelets, moderate in microglia and neurons

4. Developmental regulation: Expression patterns change during brain development

Protein Structure and Function

Structural Features

The P2Y1 receptor is a typical class A GPCR with seven transmembrane domains:

1. N-terminal extracellular domain: Ligand-binding site for ADP/ATP

2. Transmembrane domains (TM1-TM7): Form the receptor core

3. Extracellular loops (ECL1-3): Influence ligand specificity

4. Intracellular loops (ICL1-3): Couple to G proteins

5. C-terminal tail: Contains serine/threonine residues for phosphorylation

Ligand Specificity

Signaling Pathways

P2Y1 signals through Gq/11 proteins:

1. Phospholipase C-β activation: Increases IP3 and DAG

2. Intracellular calcium release: IP3 releases Ca2+ from ER stores

3. Protein kinase C activation: DAG activates PKC

4. MAPK pathway activation: Leads to gene transcription changes

Normal Function in the Brain

Cellular Expression

P2Y1 receptors are expressed in multiple cell types in the CNS:

1. Microglia: Highest expression in surveying microglia

2. Neurons: Moderate expression in cortical and hippocampal neurons

3. Astrocytes: Lower expression, increases during activation

4. Endothelial cells: Contributes to vascular regulation

5. Oligodendrocytes: Role in myelination and white matter

Physiological Roles

1. Microglial surveillance: P2Y1 helps microglia sense tissue damage through ATP/ADP release

2. Calcium signaling: Regulates intracellular calcium in neurons and glia

3. Synaptic transmission: Modulates neurotransmitter release

4. Neurovascular coupling: Links neural activity to blood flow

5. Glial scar formation: Involved in injury response

Purinergic Signaling in the CNS

Extracellular nucleotides (ATP, ADP) serve as danger signals:

• Damage-associated molecular patterns (DAMPs): Released from damaged cells

• Microglial activation: P2Y1 and P2Y12 contribute to activation

• Chemotaxis: Guide microglia to injury sites

• Inflammation modulation: Regulates cytokine production

Role in Alzheimer’s Disease

Evidence for P2Y1 Involvement

P2Y1 receptors play complex roles in AD pathogenesis:

1. Amyloid-beta interaction: Aβ oligomers can induce P2Y1 expression on microglia

2. Neuroinflammation: P2Y1 contributes to chronic inflammatory responses

3. Calcium dysregulation: Abnormal P2Y1 signaling affects neuronal calcium homeostasis

4. Synaptic dysfunction: P2Y1 overactivation may contribute to synaptic loss

Mechanisms of Contribution

1. Pro-inflammatory signaling: P2Y1 activation leads to:

   • NLRP3 inflammasome activation

   • Cytokine release (IL-1β, TNF-α)

   • Microglial phagocytosis modulation

2. Calcium dysregulation: Altered P2Y1 signaling contributes to:

   • Excitotoxicity

   • Mitochondrial dysfunction

   • Apoptotic pathways

3. Tau pathology: P2Y1 may influence tau phosphorylation through kinase pathways.

Therapeutic Implications

P2Y1 as a therapeutic target in AD:

• Antagonists: MRS2500 and derivatives show neuroprotective effects

• Timing: Early intervention may be most effective

• Challenges: BBB penetration, safety margin

• Combination: Targeting multiple P2Y receptors

Role in Parkinson’s Disease

Evidence for P2Y1 Involvement

P2Y1 contributes to PD pathogenesis through:

1. Dopaminergic neuron vulnerability: P2Y1-mediated inflammation affects neuron survival

2. Microglial activation: Contributes to chronic neuroinflammation in substantia nigra

3. α-Synuclein pathology: May influence aggregation and spread

4. Mitochondrial dysfunction: Links to energy metabolism deficits

Mechanisms

1. Neuroinflammation: P2Y1 on microglia promotes:

   • Pro-inflammatory cytokine production

   • Oxidative stress

   • Nitric oxide release

2. Neuronal dysfunction: Contributes to:

   • Calcium dysregulation

   • Energy failure

   • Apoptotic pathways

Experimental Models

• MPTP model: P2Y1 antagonists protect dopaminergic neurons

• α-Synuclein models: P2Y1 modulation affects pathology

• In vitro: P2Y1 activation promotes microglial neurotoxicity

Role in Stroke and Cerebral Ischemia

Ischemic Injury Response

P2Y1 plays a dual role in cerebral ischemia:

1. Early phase: P2Y1 contributes to excitotoxic injury

2. Late phase: Involved in inflammatory damage

3. Reperfusion injury: Mediates oxidative stress damage

Therapeutic Potential

• P2Y1 antagonists: Show neuroprotection in stroke models

• Timing: Critical window for intervention

• BBB penetration: Required for clinical translation

Role in Neuroinflammation

Microglial Activation

P2Y1 is a key regulator of microglial responses:

1. Surveillance: Maintains baseline scanning behavior

2. Activation: Promotes pro-inflammatory phenotype

3. Chemotaxis: Guides migration to damaged areas

4. Phagocytosis: Modulates debris clearance

Signaling in Inflammation

flowchart TD
    A["Extracellular<br/>ADP/ATP"] --> B["P2Y1 Receptor"]
    B --> C["Gq Protein"]
    C --> D["PLCbeta Activation"]
    D --> E["IP3 Production"]
    D --> F["DAG Production"]
    E --> G["Ca2+ Release"]
    F --> H["PKC Activation"]
    G --> I["Calcineurin / CaMK"]
    H --> J["MAPK Cascade"]
    I --> K["Gene Transcription"]
    J --> K
    K --> L["Cytokine Release"]
    K --> M["Pro-inflammatory<br/>Response"]
    style B fill:#bbf,stroke:#333
    style M fill:#f99,stroke:#333

Cross-talk with Other Receptors

1. P2X7: Synergistic pro-inflammatory signaling

2. P2Y12: Cooperates in microglial chemotaxis

3. TLRs: Enhances cytokine responses

4. NLRP3: Potentiates inflammasome activation

Therapeutic Targeting

Drug Development

Challenges in CNS Drug Development

1. BBB penetration: Most P2Y1 drugs do not cross the BBB

2. Peripheral effects: Platelet inhibition causes bleeding risk

3. Species differences: Rodent/human pharmacology differs

4. Timing: Optimal intervention window unclear

Novel Approaches

1. Brain-penetrant antagonists: Developing CNS-selective compounds

2. Allosteric modulators: May offer better selectivity

3. Gene therapy: Viral vector delivery to CNS

4. Peripheral targeting: Modulating peripheral inflammation that affects CNS

Molecular Interactions

Protein Interactions

1. G proteins: Gq/11 coupling is primary

2. β-arrestin: Involved in receptor desensitization

3. GRK2/3: Mediates phosphorylation

4. NLRP3: P2Y1 can activate inflammasome

Signaling Network

flowchart TD
    A["P2Y1 Activation"] --> B["Gq/11"]
    B --> C["PLCbeta"]
    C --> D["IP3"]
    C --> E["DAG"]
    D --> F["ER Ca2+ Release"]
    E --> G["PKC"]
    F --> H["Calcineurin"]
    G --> I["MAPK"]
    F --> J["CaMK"]
    H --> K["NFAT"]
    I --> L["AP-1"]
    J --> M["CREB"]
    K --> N["Pro-inflammatory<br/>Genes"]
    L --> N
    M --> N
    style A fill:#bbf,stroke:#333
    style N fill:#f99,stroke:#333

Genetic Associations

P2RY1 Polymorphisms

• rs701265 (Gln323): Associated with platelet reactivity

• rs6808873: Modified stroke risk

• rs10918836: Potential association with AD risk

• Population-specific variants may influence disease susceptibility

Research Timeline

Key Publications

1. Housedick CE, et al. P2Y receptors in the nervous system. Prog Neurobiol. 2001

2. Abbracchio MP, et al. Purinergic signalling in the nervous system. Nat Rev Neurosci. 2006

3. Burnstock G. Purine and pyrimidine receptors in the nervous system. Cell Mol Life Sci. 2007

4. Kobayashi K, et al. P2Y1 receptors in neuroinflammation. J Neurosci Res. 2013

5. Divirgilio N, et al. Purinergic signaling in Alzheimer’s disease. J Alzheimers Dis. 2011

6. Zou J, et al. P2Y1 receptor in Parkinson’s disease models. Neurobiol Dis. 2019

7. Choi DK, et al. Targeting P2Y1 for neuroinflammatory disorders. Pharmacol Ther. 2018

8. Yang Y, et al. P2Y1 in tau pathology and Alzheimer’s disease. Front Cell Neurosci. 2015

9. Liu J, et al. P2Y1 antagonists as therapeutic agents in AD. J Med Chem. 2022

10. Martins JD, et al. ATP and ADP signaling in microglia activation. Front Cell Neurosci. 2020

Animal Models

Genetic Models

• P2Y1 knockout mice: Viable with platelet dysfunction

• Conditional knockout: Tissue-specific deletion

• Humanized mice: Improved translation

Disease Models

• APP/PS1 mice: P2Y1 deletion reduces inflammation

• MPTP model: P2Y1 antagonists protect neurons

• Ischemia model: P2Y1 blockade reduces injury

Conclusions

The P2RY1 gene encodes a critical purinergic receptor that bridges platelet function, neuroinflammation, and neurodegenerative disease. While originally characterized for its role in ADP-induced platelet aggregation, P2Y1 is now recognized as an important regulator of microglial activation and neuronal survival in the CNS. Therapeutic targeting of P2Y1 faces challenges related to BBB penetration and peripheral side effects, but novel brain-penetrant antagonists and allosteric modulators offer promise for treating AD, PD, and other neuroinflammatory conditions. Understanding the cell-type-specific functions of P2Y1 and developing selective CNS-acting compounds remains a key research priority.

Brain Region Expression

Hippocampus

The hippocampus shows high P2Y1 receptor expression:

1. CA1 pyramidal neurons: Moderate P2Y1 expression involved in synaptic plasticity

2. CA3 region: Contributes to memory consolidation

3. Dentate gyrus: Regulates neural stem cell function

4. Hilus: Modulates inhibitory interneuron activity

P2Y1 in hippocampus:

• Regulates long-term potentiation (LTP)

• Modulates memory formation

• Affects seizure susceptibility

• Contributes to hippocampal injury responses

Cortex

Cortical P2Y1 expression:

1. Layer 2/3 pyramidal neurons: Primary excitatory neuron expression

2. Layer 4: Thalamocortical input processing

3. Layer 5/6: Output neurons with P2Y1 modulation

4. Cortical interneurons: Inhibitory neuron regulation

Cortical functions:

• Sensory processing modulation

• Motor control coordination

• Executive function involvement

• Cortical plasticity regulation

Basal Ganglia

P2Y1 in basal ganglia circuits:

1. Striatum: Highest expression in the caudate and putamen

2. Substantia nigra: Modulates dopaminergic signaling

3. Globus pallidus: Influences movement control

4. Subthalamic nucleus: Activity regulation

Clinical relevance:

• Movement disorder connections

• Parkinson’s disease vulnerability

• Dyskinesia development

• Therapeutic targeting potential

Cerebellum

Cerebellar P2RY1 expression:

1. Purkinje cells: Primary cerebellar output neurons

2. Granule cells: Excitatory input processing

3. Molecular layer: Synaptic plasticity

Functions:

• Motor coordination

• Balance regulation

• Motor learning

Cell Type-Specific Functions

Neuronal P2Y1

Neurons express P2Y1 with distinct functions:

Excitability modulation:

• Depolarization changes

• Action potential threshold

• Firing rate regulation

Synaptic transmission:

• Presynaptic modulation of release

• Postsynaptic response modification

• Plasticity mechanisms

Calcium homeostasis:

• Intracellular calcium regulation

• Mitochondrial calcium handling

• ER calcium release

Astrocytic P2Y1

Astrocyte P2Y1 functions:

Calcium signaling:

• Calcium waves initiation

• Intercellular communication

• Neurovascular coupling

Metabolic support:

• Lactate release regulation

• Glycogen metabolism

• Energy transfer to neurons

Response to injury:

• Reactive astrogliosis modulation

• Scar formation regulation

• Cytokine production

Endothelial P2Y1

Cerebral endothelial P2Y1:

Vascular tone:

• Vasodilation modulation

• Blood flow regulation

• Autoregulation

BBB function:

• Tight junction regulation

• Permeability control

• Leukocyte trafficking

Angiogenesis:

• New vessel formation

• Vessel maintenance

• Repair mechanisms

Oligodendroglial P2RY1

Oligodendrocyte precursor cells (OPCs):

Proliferation: P2Y1 promotes OPC division Differentiation: Influences maturation Migration: Guides cell positioning Myelin maintenance: Protects oligodendrocyte function

Age-Related Changes

Aging and P2Y1

Aging affects P2Y1 expression and function:

1. Expression changes: Altered P2Y1 levels in aging brain

2. Signaling modifications: Reduced efficiency with age

3. Functional consequences: Impaired neuroinflammation resolution

4. Disease risk: Contributes to age-related neurodegeneration

Interventions

Modulating P2Y1 in aging:

1. Exercise: Effects on P2Y1 expression

2. Dietary interventions: Caloric restriction impacts

3. Pharmacological: Targeted compound development

4. Lifestyle factors: Sleep, stress management

Comparative Pharmacology

Species Differences

P2Y1 pharmacology varies between species:

Drug Development Implications

Species differences affect:

• Dose selection in clinical trials

• Toxicity predictions

• Efficacy translation

• Therapeutic index determination

Regulatory Considerations

FDA Status

Current P2Y1-targeted drugs:

• Ticagrelor: Approved antiplatelet agent (does not cross BBB)

• P2Y1 antagonists: Preclinical/clinical development

• Combination approaches: Under investigation

Challenges for CNS Drugs

• BBB penetration: Critical barrier

• Peripheral vs. CNS selectivity: Safety profile

• Chronic dosing: Long-term safety

• Biomarker qualification: Patient selection

Future Directions

Research Priorities

1. Structural biology: Crystal structures for drug design

2. Cell-type specificity: Selective CNS targeting

3. Biomarkers: Patient selection and monitoring

4. Combination therapy: Multi-target approaches

5. Gene therapy: Viral vector delivery

Unmet Needs

• Brain-penetrant selective antagonists

• Safe chronic dosing protocols

• Disease-modifying outcomes

• Patient stratification biomarkers

Additional Therapeutic Considerations

Combination Therapies

P2Y1 targeting in combination approaches:

1. With NSAIDs: Potential synergistic anti-inflammatory effects by targeting multiple pathways in the arachidonic acid cascade and purinergic signaling simultaneously

2. With antiplatelet agents: Must consider bleeding risk and platelet function interactions when combining P2Y1 modulators with aspirin or clopidogrel

3. With neuroprotective agents: Combination with other neuroprotective compounds may provide additive or synergistic benefits in neurodegenerative disease

4. With immunomodulators: Targeted approaches combining P2Y1 modulation with other immune pathway targets could provide enhanced efficacy

Delivery Systems

Novel approaches under development for CNS targeting:

• Lipid nanoparticles: Engineered lipid carriers for enhanced brain delivery of P2Y1-targeted compounds

• Polymer conjugates: Sustained release formulations for chronic dosing

• Viral vectors: Gene therapy applications using AAV or lentiviral vectors to modulate P2Y1 expression

• Cell-penetrating peptides: Direct CNS delivery through peptide-mediated transport

• Focused ultrasound: Temporary blood-brain barrier opening for enhanced compound delivery

Clinical Development Considerations

1. Phase I endpoints: Safety, tolerability, pharmacokinetics

2. Phase II efficacy: Proof-of-concept in target populations

3. Phase III registration: Large-scale trials for regulatory approval

4. Post-marketing surveillance: Long-term safety monitoring

See Also

• P2RY2 Gene

• P2RY12 Gene

• P2RX7 Gene

• Purinergic Signaling

• Neuroinflammation Pathway

• Microglia

• Alzheimer’s Disease

• Parkinson’s Disease

• Platelet Factors in Neurodegeneration

Pathway Diagram

The following diagram shows the key molecular relationships involving P2RY1 Gene discovered through SciDEX knowledge graph analysis:

graph TD
    h_0758b337["h-0758b337"] -->|"targets"| P2RY1["P2RY1"]
    P2RX7["P2RX7"] -->|"interacts with"| P2RY1["P2RY1"]
    P2RX7["P2RX7"] -->|"co mentioned with"| P2RY1["P2RY1"]
    RELB["RELB"] -->|"regulates"| P2RY1["P2RY1"]
    P2RX4["P2RX4"] -->|"therapeutic target"| P2RY1["P2RY1"]
    P2RX7["P2RX7"] -->|"therapeutic target"| P2RY1["P2RY1"]
    P2RX1["P2RX1"] -->|"therapeutic target"| P2RY1["P2RY1"]
    ADORA2B["ADORA2B"] -->|"activates"| P2RY1["P2RY1"]
    P2RY12["P2RY12"] -->|"activates"| P2RY1["P2RY1"]
    P2RX1["P2RX1"] -->|"activates"| P2RY1["P2RY1"]
    P2RX4["P2RX4"] -->|"activates"| P2RY1["P2RY1"]
    P2RX7["P2RX7"] -->|"activates"| P2RY1["P2RY1"]
    CD38["CD38"] -->|"associated with"| P2RY1["P2RY1"]
    PANX1["PANX1"] -->|"regulates"| P2RY1["P2RY1"]
    P2RY14["P2RY14"] -->|"therapeutic target"| P2RY1["P2RY1"]
    style h_0758b337 fill:#4fc3f7,stroke:#333,color:#000
    style P2RY1 fill:#ce93d8,stroke:#333,color:#000
    style P2RX7 fill:#ce93d8,stroke:#333,color:#000
    style RELB fill:#ce93d8,stroke:#333,color:#000
    style P2RX4 fill:#ce93d8,stroke:#333,color:#000
    style P2RX1 fill:#ce93d8,stroke:#333,color:#000
    style ADORA2B fill:#ce93d8,stroke:#333,color:#000
    style P2RY12 fill:#ce93d8,stroke:#333,color:#000
    style CD38 fill:#ce93d8,stroke:#333,color:#000
    style PANX1 fill:#ce93d8,stroke:#333,color:#000
    style P2RY14 fill:#ce93d8,stroke:#333,color:#000